Literature DB >> 27397721

Severity of hypertension predicts the generalized neurocognitive deficit in schizophrenia.

Lindsay F Morra1, Gregory P Strauss2.   

Abstract

Individuals with schizophrenia have been found to display neurocognitive deficits on the order of 1 standard deviation below the mean of healthy controls on a range of cognitive domains, with no clear pattern of deficits that characterizes the majority of individuals with schizophrenia. Such findings have led some to suggest that schizophrenia is characterized by a "generalized" neurocognitive deficit, implying that a common underlying etiology impacts all cognitive domains. Central nervous system accounts of the generalized deficit have been proposed (e.g., NMDA and GABA interneuron receptor dysfunction); however, there may also be more diffuse "general systems" abnormalities that affect brain function. The current study evaluated the role of one type of general systems abnormality, metabolic dysfunction, on global cognitive functioning in a sample of outpatients with schizophrenia (n=27) and demographically matched healthy controls (n=33). Participants completed a battery of neuropsychological tests, as well as metabolic measurements to assess blood glucose, blood pressure, and abdominal obesity. Results indicated that higher pulse pressure predicted the generalized neurocognitive deficit in schizophrenia, but not healthy controls; however, blood glucose and abdominal obesity did not predict cognitive performance in either group. These findings provide support for the role of metabolic abnormalities in the generalized neurocognitive deficit in schizophrenia, and suggest that treatment of hypertension may be a novel adjunctive treatment target for remediating cognitive deficits in schizophrenia.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Metabolic; Neurocognition; Pulse Pressure; Schizophrenia

Mesh:

Year:  2016        PMID: 27397721      PMCID: PMC5026911          DOI: 10.1016/j.schres.2016.07.001

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  10 in total

1.  Diabetes, impaired fasting glucose, and development of cognitive impairment in older women.

Authors:  K Yaffe; T Blackwell; A M Kanaya; N Davidowitz; E Barrett-Connor; K Krueger
Journal:  Neurology       Date:  2004-08-24       Impact factor: 9.910

2.  Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia.

Authors:  Dwight Dickinson; Mary E Ramsey; James M Gold
Journal:  Arch Gen Psychiatry       Date:  2007-05

3.  Systemic hypotheses for generalized cognitive deficits in schizophrenia: a new take on an old problem.

Authors:  Dwight Dickinson; Philip D Harvey
Journal:  Schizophr Bull       Date:  2008-08-09       Impact factor: 9.306

4.  Contribution of metabolic syndrome components to cognition in older individuals.

Authors:  Miranda G Dik; Cees Jonker; Hannie C Comijs; Dorly J H Deeg; Astrid Kok; Kristine Yaffe; Brenda W Penninx
Journal:  Diabetes Care       Date:  2007-06-11       Impact factor: 19.112

Review 5.  Cognitive enhancement in schizophrenia: pharmacological and cognitive remediation approaches.

Authors:  Philip D Harvey; Christopher R Bowie
Journal:  Psychiatr Clin North Am       Date:  2012-07-15

6.  Relationship between metabolic syndrome and cognition in patients with schizophrenia.

Authors:  Jean Pierre Lindenmayer; Anzalee Khan; Saurabh Kaushik; Amod Thanju; Rajalakshmi Praveen; Lisa Hoffman; Lata Cherath; Gladys Valdez; Deborah Wance
Journal:  Schizophr Res       Date:  2012-10-26       Impact factor: 4.939

Review 7.  Pharmacological cognitive enhancement in schizophrenia.

Authors:  Philip D Harvey
Journal:  Neuropsychol Rev       Date:  2009-06-09       Impact factor: 7.444

8.  Neurophysiological correlates of metabolic syndrome and cognitive impairment in schizophrenia: a structural equation modeling approach.

Authors:  Laurent Boyer; Julien Testart; Pierre Michel; Raphaëlle Richieri; Catherine Faget-Agius; Violette Vanoye; Pascal Auquier; Christophe Lancon; Eric Guedj
Journal:  Psychoneuroendocrinology       Date:  2014-08-10       Impact factor: 4.905

9.  Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study.

Authors:  M De Hert; R van Winkel; D Van Eyck; L Hanssens; M Wampers; A Scheen; J Peuskens
Journal:  Clin Pract Epidemiol Ment Health       Date:  2006-06-27

10.  Are cardiovascular risk factors associated with verbal learning and memory impairment in patients with schizophrenia? A cross-sectional study.

Authors:  Christophe Lancon; Daniel Dassa; Jessica Fernandez; Raphaelle Richieri; Romain Padovani; Laurent Boyer
Journal:  Cardiovasc Psychiatry Neurol       Date:  2012-11-19
  10 in total
  4 in total

1.  Schizophrenia and the retina: Towards a 2020 perspective.

Authors:  Steven M Silverstein; Samantha I Fradkin; Docia L Demmin
Journal:  Schizophr Res       Date:  2019-11-07       Impact factor: 4.939

2.  Correlations between age, biomedical variables, and cognition in patients with schizophrenia.

Authors:  Wei Tang; Kai-Li Fan; Shu-Zhen Zhao; Yao-Yao Zhang; Yan Li; Sheng-Min Shao; Zheng Wang; Jiang-Qiong Ke
Journal:  Schizophr Res Cogn       Date:  2020-06-16

3.  Elevated pulse pressure and its associations with demographic and clinical parameters in a clinically representative sample of outpatients with psychotic disorders.

Authors:  Christopher Holmberg; Jarl Torgerson; Andreas Gremyr
Journal:  BJPsych Open       Date:  2022-04-07

4.  Association of cardiovascular metabolic risk factor measurements with psychiatric readmission among in-hospital patients with severe mental illness: a retrospective study.

Authors:  Xiao Wei Tan; Christopher Yi Wen Chan; Alvin Wai Mum Lum; Eng Sing Lee; Yee Ming Mok; Daniel Shuen Sheng Fung; Phern Chern Tor
Journal:  BMC Psychiatry       Date:  2022-01-18       Impact factor: 3.630

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.